BRIDGEWATER, NJ / ACCESSWIRE / November 17, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ('Tharimmune' or the 'Company'), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions announced today that it will effect a 1-for-25 reverse stock split of its issued and outstanding shares of common stock.

BRIDGEWATER，NJ/ACCESSWIRE/2023年11月17日/Tharimmune，Inc。（纳斯达克股票代码：THAR）（'Tharimmune'或'公司'），一家临床阶段生物技术公司，为罕见，炎症和肿瘤开发一系列治疗候选药物今天宣布，它将实现已发行和已发行普通股的1:25反向股票分配。

The reverse stock split was previously approved by Tharimmune stockholders at the Annual Meeting of Stockholders held on October 23, 2023, with the final ratio determined by the Company's Board of Directors. The reverse stock split will become effective at 4:01 p.m. Eastern time on November 20, 2023.

反向股票拆分先前由Tharimmune股东在2023年10月23日举行的股东年会上批准，最终比例由公司董事会确定。反向股票拆分将于2023年11月20日东部时间下午4:01生效。

Commencing with the opening of trading on The Nasdaq Capital Market ('Nasdaq') on November 21, 2023, the Company's common stock will trade on a post-split basis under its existing trading symbol 'THAR.'.

从2023年11月21日纳斯达克资本市场（纳斯达克）交易开放开始，本公司普通股将根据其现有交易标志“塔尔”进行拆分后交易。

Following the reverse stock split, the CUSIP number for the Company's common stock will be 432705200. As a result of the reverse stock split, every 25 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional shares being rounded up to the next higher whole share.

反向股票拆分后，本公司普通股的CUSIP号码为432705200。反向股票分割的结果是，已发行及已发行普通股每25股将换成普通股1股，任何分数股四舍五入至下一个较高全股。

Immediately after the reverse stock split becomes effective, the Company will have approximately 700,474 shares of common stock issued and outstanding. In addition, a proportionate adjustment will be made to outstanding equity-based awards and other equity rights..

反向股票分拆生效后，公司将立即发行并发行约700474股普通股。此外，还将按比例调整突出股权奖励和其他股权。。

The reverse stock split is primarily intended to bring the Company into compliance with Nasdaq's $1.00 per share minimum bid price requirement for continued listing; however, no assurance can be given that such reverse stock split will enable the Company to regain compliance with the Nasdaq minimum bid price requirement..

反向股票拆分主要是为了使公司遵守纳斯达克的1.00美元/股最低投标价格要求，以便继续上市；但是，不能保证这种反向股票拆分将使公司能够重新遵守纳斯达克最低投标价格要求。。

About Tharimmune, Inc.

关于Tharimmune，Inc。

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or 'uncontrollable itching' in PBC, a rare and orphan liver disease with no known cure.

Tharimmune，Inc.是一家临床阶段生物技术公司，为罕见，炎症和肿瘤疾病开发一系列治疗候选药物。该公司已获得临床阶段资产的独家全球许可，已知该资产可抑制PBC中的慢性，衰弱性瘙痒或“无法控制的瘙痒”，这是一种罕见的孤儿肝病，无法治愈。

The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets.

该公司的早期免疫肿瘤学管道包括针对独特表位的新型多特异性抗体，其具有针对多种实体瘤中众所周知的经过验证的靶标的新作用机制。Tharimmune与OmniAb，Inc.签订了许可协议，可以针对特定目标访问公司的抗体发现技术平台。

For more information please visit: www.tharimmune.com..

欲了解更多信息，请访问：www.tharimmune.com。。

Forward Looking Statements

前瞻性声明

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements.

本新闻稿中的某些陈述符合1995年“私人证券诉讼改革法”的含义。本新闻稿中包含的除历史事实陈述外的所有陈述，包括有关Tharimmune战略，未来运营，未来财务状况，预计成本，前景，计划和管理目标的陈述，均为前瞻性陈述。

The words 'anticipate,' 'believe,' 'continue,' 'could,' 'depends,' 'estimate,' 'expect,' 'intend,' 'may,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'should,' 'will,' 'would,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

“预期”，“相信”，“继续”，“可能”，“依赖”，“估计”，“期望”，“打算”，“可能”，“正在进行”，“计划”，“潜力”，“预测”，“项目”，“目标”，“应该”，“将会”，“将会”和类似的表达方式是为了识别前瞻性陈述，尽管不是所有的前瞻性陈述都包含这些标识性词语。

The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements.

公司可能实际上未达到这些前瞻性声明中披露的计划，意图或期望，您不应过分依赖这些前瞻性声明。实际结果或事件可能与这些前瞻性声明中披露的计划，意图和期望有很大不同。

Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K/A for the year ended December 31, 2022 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.

可能导致这种差异的因素包括但不限于我们在2022年12月31日结束年份的10-K/A年度报告中规定的风险因素下讨论的风险因素以及本公司提交的其他定期报告不时与证券交易委员会联系。

In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future .

此外，本新闻稿中包含的前瞻性声明代表本公司自本新闻稿发布之日起的观点。随后的事件和发展可能会导致公司的观点发生变化；但是，公司不承诺并明确拒绝任何更新或修改任何前瞻性陈述以反映新信息的义务。

Investor Relations Contact

投资者关系联系

ir@tharimmune.com

ir@tharimmune.com

www.tharimmune.com

www.tharimmune.com

SOURCE: Tharimmune, Inc.

来源：Tharimmune，Inc。

View source version on accesswire.com:

在AccessWire.com上查看源版本：

https://www.accesswire.com/804817/tharimmune-announces-1-for-25-reverse-stock-split

https://www.accesswire.com/804817/tharimmune-announces-1-for-25-reverse-stock-split